Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

14.09.17	Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
13.09.17	Biosynthesis Technology Could Transform Cannabinoid Production (PR Newswire)
13.09.17	Biosynthesis Technology Could Transform Cannabinoid Production (PR Newswire)
12.09.17	Lilly: Jardiance Tablets Reduces Cardiovascular Death Risks In Type 2 Diabetes (RTTNews)
12.09.17	Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control (PR Newswire)
11.09.17	Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress (PR Newswire)
10.09.17	Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer (PR Newswire)
09.09.17	IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine (PR Newswire)
08.09.17	Eli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study (RTTNews)
08.09.17	IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine (PR Newswire)
07.09.17	Lilly Plans To Cut About 3,500 Jobs Globally (RTTNews)
07.09.17	Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth (PR Newswire)
06.09.17	Landmark M&A Deals Continue to Shape Big Pharma (PR Newswire)
06.09.17	Landmark M&A Deals Continue to Shape Big Pharma (PR Newswire)
06.09.17	Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC) (PR Newswire)
30.08.17	Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018 (RTTNews)
30.08.17	Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018 (PR Newswire)
29.08.17	Eli Lilly To Present Data From Phase 3 Studies Of Abemaciclib, Ramucirumab (RTTNews)
29.08.17	New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress (PR Newswire)
28.08.17	Lilly to Participate in Morgan Stanley Global Healthcare Conference (PR Newswire)
17.08.17	Technical Snapshots for These Drug Makers Stocks -- Pfizer, Eli Lilly, Merck, and Sanofi (PR Newswire)
04.08.17	Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study (RTTNews)
04.08.17	Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine (PR Newswire)
31.07.17	Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular... (PR Newswire)
26.07.17	Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX (RTTNews)
25.07.17	Eli Lilly Raises 2017 Non-GAAP EPS Guidance - Quick Facts (RTTNews)
25.07.17	Eli Lilly And Co. Reports 30% Advance In Q2 Profit (RTTNews)
25.07.17	Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib (RTTNews)
25.07.17	Lilly Reports Second-Quarter Results (PR Newswire)
25.07.17	Lilly and Incyte Provide Update on Baricitinib (PR Newswire)
24.07.17	Eli Lilly Agrees With Nektar To Co-Develop NKTR - 358 (RTTNews)
24.07.17	Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy (PR Newswire)
12.07.17	Lilly Reaches Settlement Deal In US Cialis Patent Litigation (RTTNews)
12.07.17	Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation (PR Newswire)
12.07.17	Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017) (PR Newswire)
10.07.17	Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment (PR Newswire)
10.07.17	Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment (PR Newswire)
10.07.17	Lilly: FDA Files NDA For Abemaciclib For Treatment Of Advanced Breast Cancer (RTTNews)
10.07.17	FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer (PR Newswire)
07.07.17	UK Supreme Court Rules In Favor Of Lilly On Alimta Vitamin Regimen Patents (RTTNews)
07.07.17	UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents (PR Newswire)
06.07.17	Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement (PR Newswire)
06.07.17	Lilly, Purdue University Announce Strategic Research Collaboration - Quick Facts (RTTNews)
05.07.17	Breakfast Technical Briefing on Drug Makers Stocks -- Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Sanofi (PR Newswire)
03.07.17	Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts (RTTNews)
03.07.17	Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis (PR Newswire)
28.06.17	Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications (PR Newswire)
27.06.17	Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

21:14		TELL me! - der Schweizer Trading Podcast: Microsoft unter Kartellverdacht - Novartis auf einem guten Weg - bei Brenntag könnte das zyklische Tief 2025 kommen
17:58		Optimismus in Europa: Euro STOXX 50 zum Ende des Donnerstagshandels in der Gewinnzone
17:58		Freundlicher Handel in Frankfurt: LUS-DAX verbucht schlussendlich Gewinne
17:58		DAX aktuell: DAX zum Handelsende mit Zuschlägen
15:58		Börse Europa: STOXX 50-Börsianer greifen zu
12:26		Gewinne in Europa: STOXX 50 am Mittag mit Kursplus
09:28		Börse Frankfurt in Grün: DAX beginnt Handel im Plus
09:28		Freundlicher Handel in Europa: Euro STOXX 50 zum Start fester

21:14

TELL me! - der Schweizer Trading Podcast: Microsoft unter Kartellverdacht - Novartis auf einem guten Weg - bei Brenntag könnte das zyklische Tief 2025 kommen

17:58

Optimismus in Europa: Euro STOXX 50 zum Ende des Donnerstagshandels in der Gewinnzone

17:58

Freundlicher Handel in Frankfurt: LUS-DAX verbucht schlussendlich Gewinne

17:58

DAX aktuell: DAX zum Handelsende mit Zuschlägen

15:58

Börse Europa: STOXX 50-Börsianer greifen zu

12:26

Gewinne in Europa: STOXX 50 am Mittag mit Kursplus